COGT (Cogent Biosciences) Beneish M-Score: 0.00 (As of Jun. 24, 2026)

What is Cogent Biosciences Beneish M-Score?

Cogent Biosciences COGT +3.36% 25 Beneish M-Score is 0.00 as of Jun. 24, 2026. GuruFocus rates COGT with a GF Score™ of 25/100. The stock has 3 warning signs investors should review. Among 831 Biotechnology companies, Cogent Biosciences ranks worse than 120336.82% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Cogent Biosciences's Beneish M-Score or its related term are showing as below:

During the past 11 years, the highest Beneish M-Score of Cogent Biosciences was -0.45. The lowest was -25.98. And the median was -2.29.

Cogent Biosciences Beneish M-Score Related Terms

Cogent Biosciences Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Cogent Biosciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cogent Biosciences Beneish M-Score Chart

Cogent Biosciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Beneish M-Score

Get a 7-Day Free Trial

0.00

Cogent Biosciences Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Beneish M-Score	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

COGT vs SRRK, RYTM, PTCT: Beneish M-Score Comparison

For the Biotechnology subindustry, Cogent Biosciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cogent Biosciences Beneish M-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Cogent Biosciences's Beneish M-Score falls into.

Save Embed

25GF Score

Cogent Biosciences Inc COGT

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cogent Biosciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Cogent Biosciences for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 *

0.528 *

0.404 *

0.892 *

0.115 *

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 *

4.679 *

0.327 *

This Year (Mar26) TTM:

Last Year (Mar25) TTM:

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $877.80 Mil.
Total Assets was $903.01 Mil.
Property, Plant and Equipment(Net PPE) was $22.85 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.60 Mil.
Selling, General, & Admin. Expense(SGA) was $79.92 Mil.
Total Current Liabilities was $57.98 Mil.
Long-Term Debt & Capital Lease Obligation was $237.27 Mil.
Net Income was -97.352 + -102.492 + -80.93 + -73.529 = $-354.30 Mil.
Non Operating Income was -0.14 + -7.187 + -0.003 + -0.006 = $-7.34 Mil.
Cash Flow from Operations was -86.883 + -79.105 + -64.286 + -54.542 = $-284.82 Mil.

Total Receivables was $0.00 Mil.
Revenue was 0 + 0 + 0 + 0 = $0.00 Mil.
Gross Profit was 0 + 0 + 0 + 0 = $0.00 Mil.
Total Current Assets was $252.88 Mil.
Total Assets was $283.80 Mil.
Property, Plant and Equipment(Net PPE) was $26.05 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.42 Mil.
Selling, General, & Admin. Expense(SGA) was $45.49 Mil.
Total Current Liabilities was $49.32 Mil.
Long-Term Debt & Capital Lease Obligation was $15.48 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(0 / 0)	/	(0 / 0)
	=		/
	=

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (877.803 + 22.847) / 903.006)	/	(1 - (252.884 + 26.052) / 283.798)
	=	0.002609	/	0.017132
	=

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	0	/	0
	=

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(4.423 / (4.423 + 26.052))	/	(4.6 / (4.6 + 22.847))
	=	0.145135	/	0.167596
	=

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(79.921 / 0)	/	(45.486 / 0)
	=		/
	=

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((237.27 + 57.981) / 903.006)	/	((15.48 + 49.318) / 283.798)
	=	0.326965	/	0.228324
	=

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-354.303 - -7.336	-	-284.816)	/	903.006
	=	-0.068827

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 0.00 mean?

Cogent Biosciences (COGT) has a Beneish M-Score of 0.00 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cogent Biosciences and its competitors. According to the industry distribution chart, Cogent Biosciences ranks #999999 out of 831 companies in the Biotechnology industry.

Is Cogent Biosciences' Beneish M-Score too high?

Cogent Biosciences' current Beneish M-Score is 0.00. Based on the distribution chart, Cogent Biosciences ranks #999999 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cogent Biosciences has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.

How does Cogent Biosciences' Beneish M-Score compare to SRRK and RYTM?

According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #999999 out of 831 companies for Beneish M-Score. This places Cogent Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Biotechnology company?

A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cogent Biosciences stock overvalued right now?

Cogent Biosciences (COGT) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Cogent Biosciences' overall GF Score™ is 25/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Beneish M-Score is 0.00 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cogent Biosciences Business Description

Industry Healthcare Biotechnology

Comparable Companies SRRK RYTM PTCT TGTX APGE MIRM SYRE PTGX CGON CELC VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 275 Wyman Street, 3rd Floor, Waltham, MA, USA, 02451

Website https://www.cogentbio.com

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

25GF Score

Get the complete analysis for COGT

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$37.53

Price

View COGT Analysis

See Beneish M-Score data for all stocks →